ReviewCurrent obesity reports2022
Highlighting the Role of Obesity and Insulin Resistance in Type 1 Diabetes and Its Associated Cardiometabolic Complications.
Review in Current obesity reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Control-IQ Technology Use in Individuals With High Insulin Requirements: Results From the Multicenter Higher-IQ Trial.Journal of diabetes science and technology · 2024Trial
- Insulin Resistance Indices and Cardiovascular Disease Risk in Middle-Aged and Older Adults with Prediabetes: A Machine Learning-Assisted Predictive Modeling Study.Healthcare (Basel, Switzerland) · 2026Article
- Obesity in Adults with Type 1 Diabetes Mellitus.Journal of obesity & metabolic syndrome · 2026Review
- Insulin gene-modified 3D stem cells for enhanced islet regeneration and systemic reversal of type 1 diabetes.Stem cells translational medicine · 2026Article
- Article
- Distinct Circulating Biomarker Profiles Associated with Type 2 Diabetes in a Regional Cohort-A Cross-Sectional Study.Metabolites · 2025Article
- Article
- Leonurine (SCM-198) exerts protective effects on pancreatic β-cells in type 1 diabetes by modulating the Bax/Bcl-2/Caspase-3 signaling pathway.BMC complementary medicine and therapies · 2025Article
- Incidence of type 1 diabetes in Gansu Province, Northwest China from 2018 to 2022: a multicenter, hospitalization-based study.Acta diabetologica · 2025Article
- Various classification methods for diabetes mellitus in the management of blood glucose control.World journal of diabetes · 2025Article
- Insulin Resistance in Type 1 Diabetes: Pathophysiological, Clinical, and Therapeutic Relevance.Endocrine reviews · 2025Review
- Hemoglobin glycation index among adults with type 1 diabetes: Association with double diabetes features.World journal of diabetes · 2025Article
- Association between anthropometric indices and chronic kidney disease: Insights from NHANES 2009-2018.PloS one · 2025Article
- Serum and urinary levels of MIF, CD74, DDT and CXCR4 among patients with type 1 diabetes mellitus, type 2 diabetes and healthy individuals: Implications for further research.Metabolism open · 2024Article
- Metabolic health in people living with type 1 diabetes in Belgium: a repeated cross-sectional study.Diabetologia · 2024Article
- Glucagon-like peptide-1 agonists: Role of the gut in hypoglycemia unawareness, and the rationale in type 1 diabetes.World journal of diabetes · 2024Article
- Effect of Body Weight on Glycaemic Indices in People with Type 1 Diabetes Using Continuous Glucose Monitoring.Journal of clinical medicine · 2024Article
- Association of triglyceride-glucose index with severity of coronary artery disease among male patients.Scientific reports · 2024Article
- Diet patterns, gut microbiota and metabolic disorders: Perspectives and challenges.Metabolism open · 2024Article
- Change in Body Mass Index in Youth in the First 5 Years After Type 1 Diabetes Mellitus Diagnosis.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThis narrative review appraises research data on the potentially harmful effect of obesity and insulin resistance (IR) co-existence with type 1 diabetes mellitus (T1DM)-related cardiovascular (CVD) complications and evaluates possible therapeutic options. RECENT
findingsObesity and IR have increasingly been emerging in patients with T1DM. Genetic, epigenetic factors, and subcutaneous insulin administration are implicated in the pathogenesis of this coexistence. Accumulating evidence implies that the concomitant presence of obesity and IR is an independent predictor of worse CVD outcomes. The prevalence of obesity and IR has increased in patients with T1DM. This increase can be partly attributed to general population trends but, additionally, to iatrogenic weight gain caused by insulin treatment. This association might be the missing link explaining the excess CVD burden observed in patients with T1DM despite optimal glycemic control. Data on newer agents for type 2 diabetes mellitus (T2DM) treatment are unraveling novel ways to challenge this aggravating coexistence.
Indexed as
Identifiers
35931912What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.